We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-7.31%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$118M
(+7.2%)
Cap. Flow
+$242M
Cap. Flow
% of AUM
13.74%
Top 10 Holdings %
Top 10 Hldgs %
58.08%
Holding
55
New
13
Increased
19
Reduced
5
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$94.3M |
| 2 |
Quest Diagnostics
DGX
|
+$88.9M |
| 3 |
DexCom
DXCM
|
+$68.5M |
| 4 |
Edwards Lifesciences
EW
|
+$60.4M |
| 5 |
Zimmer Biomet
ZBH
|
+$59.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$112M |
| 2 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$105M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$83M |
| 4 |
Abbott
ABT
|
+$74.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$59.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.19% |
| 2 | Financials | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$18.4B
| $160M | 9.06% |
1,545,000
+618,000
| +67% | +$59.8M |
|
|
2
Quest Diagnostics
DGX
$25.9B
| $132M | 7.49% |
1,850,000
+1,325,350
| +253% | +$88.9M |
|
|
3
DexCom
DXCM
$28.8B
| $121M | 6.83% |
7,100,000
+4,100,000
| +137% | +$68.5M |
|
4
Labcorp
LH
$25.9B
| $111M | 6.3% |
1,105,800
+174,600
| +19% | +$16.7M |
|
|
MNK
5
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $106M | 5.99% |
1,725,000
+1,475,610
| +592% | +$94.3M |
|
|
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
| $92.7M | 5.25% |
2,015,000
-285,000
| -12% | -$10.3M |
|
7
Universal Health Services
UHS
$9.88B
| $78M | 4.42% |
625,000
+258,610
| +71% | +$29.1M |
|
8
PUT
iShares Russell 2000 ETF
IWM
$80.2B
| $77.4M | 4.39% |
+700,000
| New | +$72.5M |
|
|
AKRX
9
DELISTED
Akorn Inc
AKRX
| $74.7M | 4.23% |
3,175,000
+1,175,000
| +59% | +$30.9M |
|
|
10
Edwards Lifesciences
EW
$50B
| $72.8M | 4.12% |
2,475,000
+2,187,720
| +762% | +$60.4M |
|
11
HCA Healthcare
HCA
$85.7B
| $66.3M | 3.76% |
850,000
+838,820
| +7,503% | +$58.6M |
|
|
AET
12
DELISTED
Aetna Inc
AET
| $56.2M | 3.18% |
+500,000
| New | +$53.5M |
|
13
Thermo Fisher Scientific
TMO
$214B
| $53.1M | 3.01% |
+375,000
| New | +$50.3M |
|
|
BCR
14
DELISTED
CR Bard Inc.
BCR
| $52.7M | 2.99% |
260,000
-440,000
| -63% | -$83M |
|
15
Pfizer
PFE
$142B
| $47.4M | 2.69% |
1,686,400
+31,483
| +2% | +$899K |
|
16
Encompass Health
EHC
$11B
| $41.4M | 2.35% |
+1,382,700
| New | +$38.2M |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $38.4M | 2.18% |
2,000,000
+475,000
| +31% | +$10.1M |
|
18
Humana
HUM
$44B
| $36.6M | 2.07% |
+200,000
| New | +$34.7M |
|
19
Icon
ICLR
$12.8B
| $30.1M | 1.71% |
401,400
+1,400
| +0.4% | +$98.1K |
|
20
Neurocrine Biosciences
NBIX
$18.7B
| $28.7M | 1.62% |
+725,000
| New | +$28.8M |
|
21
Waters Corp
WAT
$37.3B
| $26.1M | 1.48% |
+198,039
| New | +$24.7M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $24.2M | 1.37% |
+430,877
| New | +$25.4M |
|
23
Teva Pharmaceuticals
TEVA
$41.2B
| $22.5M | 1.27% |
419,760
-570,750
| -58% | -$33.5M |
|
|
PRAH
24
DELISTED
PRA Health Sciences, Inc.
PRAH
| $22.2M | 1.26% |
+520,000
| New | +$22M |
|
25
Collegium Pharmaceutical
COLL
$1.17B
| $22.2M | 1.26% |
1,225,000
+200,000
| +20% | +$3.64M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2016 Portfolio in Review
As of Q1 2016, HealthCor Management held 55 positions worth $1.76B, up 7.2% from $1.65B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
HealthCor Management deployed $242M of net new capital in Q1 2016, opening 13 new positions and adding to 19 existing holdings. Its largest new stake was Aetna Inc: 500,000 shares worth $56.2M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 72% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was CR Bard Inc., an estimated $83M trimmed.
- HealthCor Management's largest Q1 2016 buy was Aetna Inc: 500,000 shares worth $56.2M.
- HealthCor Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2016, an estimated $94.3M increase.
- HealthCor Management's biggest Q1 2016 reduction was CR Bard Inc., cutting an estimated $83M.
- HealthCor Management fully exited Eli Lilly in Q1 2016, selling an estimated $112M.
- HealthCor Management's ten largest holdings make up 58% of its $1.76B portfolio in Q1 2016.
- HealthCor Management opened 13 new positions and closed 17 in Q1 2016.
- HealthCor Management's portfolio value rose 7.2% quarter-over-quarter to $1.76B.
Based on HealthCor Management's 13F filing for Q1 2016, filed 16 May 2016.